



## **Emiliano Calvo, MD, PhD**

Prof Calvo earned his Medical Degree in 1993 at the Universidad Autónoma de Madrid in Madrid, Spain and his PhD in 2003 at the Universidad de Navarra in Pamplona, Spain. He trained in Medical Oncology at the Clínica Universitaria de Navarra in Pamplona, Spain and completed his Advanced Fellowship in Drug Development at the Cancer Therapy & Research Center's Institute for Drug Development in San Antonio, Texas, from 2003 to 2005, where he was a Senior Fellow and Clinical Investigator.

While working in the Medical Oncology Department at the Hospital Vall d'Hebron in Barcelona, Spain, from 2005 to 2008, Dr Calvo was Co-Director and Senior Researcher of the Phase I Unit and director of the Genitorurinary Tumors Programme.

Prof Calvo is the Director of START Madrid Group in Madrid (Early Phase Clinical Drug Development in Oncology, international programme) and has been the Director of Clinical Research at the START Madrid-Centro Integral Oncológico Clara Campal hospital, in Madrid, Spain, since its launch in 2008. He is also the President of the Investigational Therapeutics in Oncological Sciences Foundation (Intheos). In addition, he is an Associate Professor at University CEU San Pablo in Madrid, Spain.

Prof Calvo is a member of the ESMO Faculty Group Principles of Clinical Trials and Systemic Therapy. He has been a member of the Scientific Committee of the ESMO-ECCO annual meeting (2008, 2009 and 2011 –Developmental Therapeutics track-) and, since 2015, at the annual EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics. He is also the ESMO International Workshop in Methods in Clinical Cancer Research co-Director (2017-2019), in Flims, Switzerland; Prof Calvo is Track Leader (2015-6) and Committee member (since 2014) for the Scientific Programme Committee on the Developmental Therapeutics - Clinical Pharmacology & Experimental Track of the Annual Meetings of the American Society of Clinical Oncology (ASCO), as well as honorary member of the Cancer Education Committee of ASCO (2015-2016).

Prof Calvo has co-authored approximately one hundred publications, including scientific articles, chapters in oncology books and presentations at different major conferences and meetings, especially focusing on clinical development of new drugs in different tumour types and in kidney cancer. He serves as an ad-hoc reviewer of various oncology journals, and has recently been appointed board editor for European Journal of Cancer. He is a panel expert advisor at multiple Advisory Boards of anticancer drug development and kidney cancer therapeutics. During the last 12 years of almost full dedication to Clinical Drug development in Oncology, he has participated in around two hundred international studies, as a clinical investigator, especially in Early Clinical Drug Development and in kidney cancer.